14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ADUS vs AHCO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADUS vs AHCO. Trailing 12-month operating profitability (ADUS 10.4% vs AHCO 3.8%) and valuation multiples (ADUS 16.1x vs AHCO 7.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment14.4% of Rev ($495M)
90D Engineering Disclosures0 Published
Investor FAQ ADUS vs AHCO Key Questions & Quantitative Answers
As of Nov 20, 2026, Addus HomeCare Corp. (ADUS) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas AHCO carries 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin). Technically, ADUS sits in a Markup phase (RSI 51.6, UNCLASSIFIED options structure) and AHCO sits in a Markup phase (RSI 57.1, SURGE options structure).
AHCO leads the Growth & Scale pillar: ADUS posts +7.0% YoY revenue growth and +24.2% YoY earnings growth on $1.50B TTM revenue (32.3% gross margin, 10.4% operating margin), compared with AHCO at +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin). On trailing 12-month operating scale, ADUS generates $1.50B in USD-normalized revenue versus $3.44B for AHCO. In operating R&D and SG&A reinvestment, ADUS deploys 21.9% of Rev ($329M) (0 90-day corporate R&D disclosures) versus 14.4% of Rev ($495M) (0 disclosures) for AHCO.
AHCO screens cheaper on headline valuation multiples. ADUS trades at 16.1x Forward P/E, 20.1x Trailing P/E, 1.05x PEG, and 1.5x EV/Revenue (11.5% EBITDA margin), whereas AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADUS (10.0% ROE) versus AHCO (-28.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ADUS carries 21.9% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 21% Vol realized risk). By comparison, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.